Caveolin as a potential drug target for cardiovascular protection

被引:18
作者
Sellers, Stephanie L.
Trane, Andy E.
Bernatchez, Pascal N.
机构
[1] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V6Z 1Y6, Canada
[2] Univ British Columbia, James Hogg Res Ctr, Vancouver, BC V6Z 1Y6, Canada
来源
FRONTIERS IN PHYSIOLOGY | 2012年 / 3卷
关键词
caveolin-1; caveolin-3; caveolae; cardioprotection; nitric oxide; therapeutics; cardiovascular disease; NITRIC-OXIDE SYNTHASE; MYOCARDIAL INFARCT SIZE; CARDIAC-SPECIFIC OVEREXPRESSION; P42/44 MAP KINASE; TERM NITRATE USE; ENDOTHELIAL DYSFUNCTION; SCAFFOLDING DOMAIN; MICROVASCULAR PERMEABILITY; PULMONARY-HYPERTENSION; HEART-FAILURE;
D O I
10.3389/fphys.2012.00280
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Caveolae and caveolin are key players in a number of disease processes. Current research indicates that caveolins play a significant role in cardiovascular disease and dysfunction. The far-reaching roles of caveolins in disease and dysfunction make them particularly notable therapeutic targets. In particular, caveolin-1 (Cav-1) and caveolin-3 (Cav-3) have been identified as potential regulators of vascular dysfunction and heart disease and might even confer cardiac protection in certain settings. Such a central role in vascular health therefore makes manipulation of Cav-1/3 function or expression levels clear therapeutic targets in a variety of cardiovascular related disease states. Here, we highlight the role of Cav-1 and Cav-3 in cardiovascular health and explore the potential of Cav-1 and Cav-3 derived experimental therapeutics.
引用
收藏
页数:10
相关论文
共 103 条
[1]   Protective role of endothelial nitric oxide synthase [J].
Albrecht, EWJA ;
Stegeman, CA ;
Heeringa, P ;
Henning, RH ;
van Goor, H .
JOURNAL OF PATHOLOGY, 2003, 199 (01) :8-17
[2]   Epithelial expression of caveolin-2, but not caveolin-1, is enhanced in the inflamed mucosa of patients with ulcerative colitis [J].
Andoh, A ;
Saotome, T ;
Sato, T ;
Tsujikawa, T ;
Araki, Y ;
Fujiyama, Y ;
Bamba, T .
INFLAMMATORY BOWEL DISEASES, 2001, 7 (03) :210-214
[3]  
ANSHELEVICH M, 1994, LANCET, V344, P91
[4]   The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells [J].
Batova, Suzan ;
DeWever, Julie ;
Godfraind, Theophile ;
Balligand, Jean-Luc ;
Dessy, Chantal ;
Feron, Olivier .
CARDIOVASCULAR RESEARCH, 2006, 71 (03) :478-485
[5]   Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis [J].
Bauer, PM ;
Yu, J ;
Chen, Y ;
Hickey, R ;
Bernatchez, PN ;
Looft-Wilson, R ;
Huang, Y ;
Giordano, F ;
Stan, RV ;
Sessa, WC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (01) :204-209
[6]   Resolution of ST-segment elevation following intravenous administration of nitroglycerin and verapamil [J].
Beltrame, JF ;
Stewart, S ;
Leslie, S ;
Poropat, S ;
Horowitz, JD .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (04) :452-+
[7]   A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice [J].
Bernatchez, Pascal ;
Sharma, Arpeeta ;
Bauer, Philip M. ;
Marin, Ethan ;
Sessa, William C. .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (09) :3747-3755
[8]   Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides [J].
Bernatchez, PN ;
Bauer, PM ;
Yu, J ;
Prendergast, JS ;
He, PN ;
Sessa, WC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) :761-766
[9]   In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation [J].
Bucci, M ;
Gratton, JP ;
Rudic, RD ;
Acevedo, L ;
Roviezzo, F ;
Cirino, G ;
Sessa, WC .
NATURE MEDICINE, 2000, 6 (12) :1362-1367
[10]   Cardioplegic arrest with L-arginine improves myocardial protection:: Results of a prospective randomized clinical trial [J].
Carrier, M ;
Pellerin, M ;
Perrault, LP ;
Bouchard, D ;
Pagé, P ;
Searle, N ;
Lavoie, J .
ANNALS OF THORACIC SURGERY, 2002, 73 (03) :837-841